Mirum Pharmaceuticals, Inc.
(MIRM)
Mirum Pharmaceuticals Is Priced for the Drug That Stumbled, Not the Four That Worked
Since late September, Mirum Pharmaceuticals has put a fourth medicine on the U.S. market, reported that its hepatitis delta antibody met the primary endpoint of a pivotal Phase 3 trial, and reported that its commercial lead drug met the primary endpoint of a second Phase 3 in ...
Read Article ›